FY2024 Earnings Forecast for BPMC Issued By Zacks Research

Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) - Equities research analysts at Zacks Research issued their FY2024 earnings per share estimates for Blueprint Medicines in a research note issued to investors on Monday, November 18th. Zacks Research analyst A. Chakraborty forecasts that the biotechnology company will post earnings of ($3.87) per share for the year. The consensus estimate for Blueprint Medicines' current full-year earnings is ($3.61) per share. Zacks Research also issued estimates for Blueprint Medicines' Q4 2024 earnings at ($0.86) EPS, Q1 2025 earnings at ($0.85) EPS, Q2 2025 earnings at ($0.77) EPS, Q3 2025 earnings at ($0.52) EPS, Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($2.37) EPS, Q1 2026 earnings at ($0.06) EPS, Q2 2026 earnings at $0.00 EPS, Q3 2026 earnings at $0.07 EPS and FY2026 earnings at $0.25 EPS.

Other analysts have also recently issued reports about the company. Barclays lifted their price objective on Blueprint Medicines from $75.00 to $105.00 and gave the company an "equal weight" rating in a research report on Monday, July 29th. HC Wainwright restated a "buy" rating and set a $135.00 price target on shares of Blueprint Medicines in a research report on Friday, November 15th. Baird R W upgraded Blueprint Medicines to a "strong-buy" rating in a report on Friday, August 2nd. Guggenheim raised their price objective on Blueprint Medicines from $130.00 to $138.00 and gave the company a "buy" rating in a research report on Friday, August 2nd. Finally, Wells Fargo & Company reduced their target price on shares of Blueprint Medicines from $153.00 to $151.00 and set an "overweight" rating on the stock in a research report on Thursday, October 31st. One analyst has rated the stock with a sell rating, seven have given a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $122.11.

Blueprint Medicines Price Performance

Shares of NASDAQ BPMC opened at $94.81 on Thursday. Blueprint Medicines has a 1 year low of $64.79 and a 1 year high of $121.90. The stock has a market capitalization of $6.02 billion, a P/E ratio of -44.93 and a beta of 0.59. The company's 50-day moving average is $90.00 and its 200 day moving average is $98.70. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.32 and a quick ratio of 3.27.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.97) by $0.08. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. The business had revenue of $128.20 million for the quarter, compared to the consensus estimate of $127.56 million. During the same period in the previous year, the firm earned ($2.20) EPS. The company's quarterly revenue was up 126.5% compared to the same quarter last year.

Insider Activity

In other news, insider Fouad Namouni sold 3,633 shares of the firm's stock in a transaction on Thursday, October 3rd. The stock was sold at an average price of $89.32, for a total value of $324,499.56. Following the transaction, the insider now directly owns 69,070 shares in the company, valued at $6,169,332.40. This trade represents a 5.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders own 4.21% of the company's stock.

Institutional Trading of Blueprint Medicines

Hedge funds have recently bought and sold shares of the company. Triad Wealth Partners LLC bought a new stake in shares of Blueprint Medicines during the 2nd quarter valued at about $27,000. Covestor Ltd raised its position in Blueprint Medicines by 9,700.0% in the first quarter. Covestor Ltd now owns 294 shares of the biotechnology company's stock worth $28,000 after acquiring an additional 291 shares during the period. Quarry LP purchased a new position in shares of Blueprint Medicines during the 3rd quarter worth $32,000. Natixis bought a new stake in shares of Blueprint Medicines during the 1st quarter valued at $73,000. Finally, Quantbot Technologies LP purchased a new stake in shares of Blueprint Medicines in the 3rd quarter worth $108,000.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.